THERAPY DOSSIER · th-c96687ea4971

TNF-alpha siRNA in mannose-modified trimethyl chitosan-cysteine nanoparticles (en-MTC nanoparticles)

Other

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 25662912 ↗2015Reported benefit

Optimization of multifunctional chitosan-siRNA nanoparticles for oral delivery applications, targeting TNF-alpha silencing in rats.

RatChemical/toxinSprague-DawleyMaleOral50 micrograms per kg siRNA

Model: Acute hepatic injury driven by systemic TNF-alpha

Orally delivered en-MTC nanoparticles at 50 micrograms per kg siRNA inhibited systemic TNF-alpha production, lowered TNF-alpha mRNA in liver, spleen and lung and protected rats from acute hepatic injury.

Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…